Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2008

View Archived Issues

Hedgehog pathway inhibitor shows potential benefits in cancer models

LRG-47: a novel therapeutic target in multiple sclerosis

Low relapse rate and MRI activity in MS with oral FTY-720 in 30-month extension study

Lumiliximab activity is independent of antigen expression levels in lymphocytic leukemia cells

Nippon Shinyaku receives approval for dysmenorrhea agent in Japan

ABT-263 improves oral bioavailability and potency of Bcl-2 family protein inhibitors

Schering-Plough receives Japanese approval for Aroglycem

ARRY-520 enters phase I/II clinical evaluation

JAK2 inhibitor INCB-18424 to be evaluated in phase II studies

Boston Scientific receives Canadian approval for sale of Taxus Liberte coronary stent

BrainCells initiates phase II clinical trial of BCI-540 for depression with anxiety

Novel antithrombotic agents disclosed in recent Portola patent

Recent Schering patents divulge new analgesic agents

Romark initiates enrollment in phase II clinical trial of Alinia in hepatitis C

Preclinical activity of Aurora kinase B/C inhibitor GSK-1070916A described

CD-200-Fc significantly improves arthritis in mouse model

Alseres opens seven enrollment sites for first stage of Altropane phase III clinical trial program

Innocoll initiates dosing in phase II clinical trial of CollaRx gentamicin topical sponge

CSL Behring submits NDS to Health Canada for approval of C1-esterase inhibitor for HAE

Raptor initiates phase IIa Convivia study in subjects with ALDH2 deficiency

Thalidomide Pharmion granted E.U. marketing authorization for multiple myeloma

Recent Speedel patent reports novel antihypertensive agents

Sutent approved in Japan for GIST and renal cell carcinoma

Champix set for Japanese launch

Bayer launches Nexavar in Japan for recurrent renal carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...